J. Selleslach

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

R. Sciot, H. Wildiers, A. V. van Oosterom, 2006, Sarcoma.

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Clinical Cancer Research.

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

A. Awada, S. Bartholomeus, T. Gil, 2008 .

Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.

J. Verweij, A. V. van Oosterom, A. Sparreboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

A. V. van Oosterom, E. D. de Bruijn, R. Maes, 2007, Anti-cancer drugs.

Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

A. Awada, S. Bartholomeus, T. Gil, 2010 .